NDC product
Xtandi
NDC 0469-1725 · Astellas Pharma US, Inc.
Key facts
| Product NDC | 0469-1725 |
|---|---|
| Proprietary name | Xtandi |
| Nonproprietary name | enzalutamide |
| Substances | ENZALUTAMIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Astellas Pharma US, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA213674 |
| Pharmacologic classes | Androgen Receptor Antagonists [MoA], Androgen Receptor Inhibitor [EPC], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA] |
| Marketing start | Aug 4, 2020 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: